CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $39.04, but opened at $41.30. CochLear shares last traded at $41.30, with a volume of 2,299 shares changing hands.
Analyst Ratings Changes
CHEOY has been the subject of several recent research reports. Jefferies Financial Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. UBS Group downgraded shares of CochLear from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 23rd. Zacks Research upgraded shares of CochLear from a “strong sell” rating to a “hold” rating in a research note on Monday, June 22nd. Finally, Royal Bank Of Canada downgraded shares of CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price objective on the stock. in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, CochLear presently has a consensus rating of “Hold” and an average price target of $117.00.
Check Out Our Latest Stock Analysis on CochLear
CochLear Stock Performance
About CochLear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Read More
- Five stocks we like better than CochLear
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
